We have reported that inhibition of NF-κB using various drugs could enhance the therapeutic efficacy or improve radiotherapy outcome in PCa, oral cancer, hepatoma and colorectal cancer [37,47–52]. This evidence concerns the gene NFKB1 and lip and oral cavity carcinoma.